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license (http://creativemultiple genetic and pathological causes. It is characterized by both cortical and subcortical atro-
phies, with previous studies showing early involvement of the amygdala. However, no prior study
has specifically investigated the atrophy of different subnuclei of the amygdala.
Methods: Using an automated segmentation tool for T1-weighted volumetric magnetic resonance
imaging, we investigated amygdalar subnuclei (AS) involvement in a cohort of 132 patients with ge-
netic or pathologically confirmed FTD (age: mean5 61 years (standard deviation5 8); disease dura-
tion: 5 (3) years) compared with 107 age-matched controls.
Results: AS were affected in all genetic and pathological forms of FTD.MAPTmutations/FTDP-17,
Pick’s disease, and transactive response DNA binding protein 43 kDa type C were the forms with the
smallest amygdala (35%–50% smaller than controls in the most affected hemisphere, P, .0005). In
most FTD groups, medial subnuclei (particularly the superficial, accessory basal and basal/paralami-
nar subnuclei) tended to be affected more than the lateral subnuclei, except for the progressive supra-
nuclear palsy group, in which the corticoamygdaloid transition area was the least-affected area.
Discussion: Differential involvement of the AS was seen in the different genetic and pathological
forms of FTD. In general, the most affected subnuclei were the superficial, accessory basal and
basal/paralaminar subnuclei, which form part of a network of regions that control reward and emotion
regulation, functions known to be particularly affected in FTD.
 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Amygdala; Frontotemporal dementia; Imaging; MRI; Volumetry1. Introduction
Frontotemporal dementia (FTD) is a heterogeneous
neurodegenerative disorder. Genetically, around a third of
patients with FTD have an autosomal dominant mutation
in microtubule-associated protein tau (MAPT), progranulins: J.D.R. has been on the Medical Advisory Board for
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commons.org/licenses/by-nc-nd/4.0/).(GRN), and chromosome 9 open reading frame 72
(C9orf72) [1]. Neuropathologically, the three most common
abnormalities in the brain are tau, transactive response DNA
binding protein 43 kDa (TDP-43), and fused in sarcoma in-
clusions [2,3]. Atrophy in the medial temporal lobe is a
common feature in cases of FTD, and the amygdala is
often affected in the early stages of the illness, particularly
in carriers of mutations in the MAPT gene [4,5] where
volume loss has been seen on magnetic resonance imaging
10-15 years before the expected onset [6]. Neuropatholog-
ical investigations have also shown amygdalar involvement,
e.g., one study described severe volume loss of 52% in FTDimer’s Association. This is an open access article under the CC BY-NC-ND
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whereas another study showed TDP-43 inclusions in the ba-
solateral nucleus of the amygdala in the earliest stage of the
disease [8].
The amygdala is composed of different subnuclei with
connections to the limbic system, as well as to the rest of
the brain [9–12]. These are involved in reward learning,
motivation, emotion, and several cognitive functions such
as attention, perception, and explicit memory [10] (Fig. 1).
Owing to recent advances in parcellation methods, it is
possible to measure these amygdalar subnuclei (AS)
in vivo on magnetic resonance scans [15]. We aimed to
investigate the pattern of atrophy of the AS in a cohort
with a genetic or pathologically confirmed diagnosis of
FTD to clarify whether and to what extent the AS are
impaired across these different forms of FTD.2. Methods
We reviewed the UCL Dementia Research Center FTD
magnetic resonance imaging (MRI) database to identify pa-
tients with a genetic or pathologically confirmed diagnosis
of FTD and a usable T1-weighted magnetic resonance
scan. A total of 132 patients were identified (Table 1).
Seventy-five patients were carriers of a mutation in one of
the FTD-associated genes: 27 with a mutation in MAPT
[16,17], 18 in GRN [18,19], 29 in chromosome 9 openFig. 1. Schematic representation of the amygdala subnuclei and their functions an
tem. The graph is based on the following studies [9–11,13,14]. Anatomical delinereading frame 72 (C9orf72) [20,21], and one with a dual
mutation in both GRN and C9orf72, who was excluded
from the genetic analysis. For 79 patients, postmortem
confirmation of the underlying neuropathology was
available: fused in sarcoma (n 5 3), TDP-43 type A
(n 5 16), TDP-43 type B (n 5 3), TDP-43 type C
(n 5 20); Pick’s disease (n 5 17), progressive supranuclear
palsy (n 5 4), corticobasal degeneration (n 5 9), and
frontotemporal dementia with parkinsonism linked to
chromosome 17 (FTDP-17) (n 5 7). There was an overlap
of 21 cases between the genetic groups and the pathological
groups: 5 patients with GRNmutation had TDP-43 type A, 7
with C9orf72 mutation had TDP-43 type A and 2 had TDP-
43 type B, and 7 withMAPTmutation had FTDP-17; the pa-
tient with dual GRN/C9orf72 mutation had TDP-43 type A.
A total of 107 cognitively normal subjects, with a similar age
to the patients and a usable volumetric T1-weighted MRI,
were identified as controls. The study was approved by the
local ethics committee, and written informed consent was
obtained from all participants.
No significant age difference was seen between the FTD
groups and controls (Table 1). Among the genetic groups,
the GRN group had a shorter disease duration (3.2 [2.8]
years) than the C9orf72 (5.5 [3.2], P 5 .040) and MAPT
(5.7 [3.2], P 5 .002) groups, but no difference for disease
duration was found among the pathological groups
(P 5 .722, analysis of variance). No difference was foundd connections. Red-bordered boxes and subnuclei are part of the limbic sys-
ation of the subnuclei is based on the study by Saygin et al. [15].
Table 1











Scanner (1.5 T GE/3T
Siemens Trio/3T
Siemens Prisma)
Controls 107 — 62.7 (11.3) 44% — 35/56/16
Genetic MAPT 27 26/0/0/1/0 56.0 (7.6) 63% 5.7 (3.2) 13/11/3
GRN 18 11/0/0/5/2 62.0 (6.4) 56% 3.2 (2.8) 8/5/5
C9orf72 29 24/3/0/2/0 62.1 (6.8) 69% 5.5 (3.2) 10/14/5
Pathology FTDP-17 7 7/0/0/0/0 51.3 (5.8) 71% 5.2 (3.1) 6/1/0
Tau-Pick’s 17 9/0/3/4/1 59.7 (4.2) 76% 4.4 (2.2) 14/3/0
Tau-PSP 4 2/0/0/2/0 77.1 (7.6) 100% 5.4 (4.4) 2/1/1
Tau-CBD 9 5/0/0/4/0 61.9 (9.2) 78% 4.6 (0.9) 6/3/0
TDP-43 type A 16 11/1/0/3/1 60.9 (7.4) 63% 3.4 (1.7) 9/7/0
TDP-43 type B 3 3/0/0/0/0 57.1 (7.7) 67% 4.8 (2.7) 3/0/0
TDP-43 type C 20 0/0/19/1/0 65.3 (7.3) 65% 4.7 (2.7) 16/4/0
FUS 3 3/0/0/0/0 43.9 (13.6) 67% 3.3 (2.1) 3/0/0
Abbreviations: bvFTD, behavioral variant of frontotemporal dementia; FTD-MND, frontotemporal dementia with associated motor neurone disease; svPPA,
semantic variant of primary progressive aphasia; nfvPPA, nonfluent variant of primary progressive aphasia; PPA-NOS, primary progressive aphasia not other-
wise specified; SD, standard deviation; FTDP-17, frontotemporal dementia with Parkinsonism linked to chromosome 17; PSP, progressive supranuclear palsy;
CBD, corticobasal degeneration; TDP-43, transactive response DNA binding protein 43 kDa; FUS, fused in sarcoma.
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used (P 5 .413, chi-square test), but there was a difference
for the pathological groups (P , .0005, chi-square test).
T1-weighted MRIs were acquired from 1993 to 2018 us-
ing scanners from three different manufacturers: 110 on
1.5 T Signa MRI scanner (GEMedical systems, Milwaukee,
WI, repetition time5 12 ms, inversion time5 650 ms, echo
time 5 5 ms, acquisition matrix 5 256 ! 256, spatial
resolution5 1.5 mm), 99 on 3T Trio MRI scanner (Siemens,
Erlangen, Germany, repetition time 5 2200 ms, inversion
time 5 900 ms, echo time 5 2.9 ms, acquisition
matrix 5 256 ! 256, spatial resolution 5 1.1 mm), and
30 on 3T Prisma MRI scanner (Siemens, Erlangen, Ger-
many, repetition time 5 2000 ms, inversion
time 5 850 ms, echo time 5 2.93 ms, acquisition
matrix 5 256! 256, spatial resolution 5 1.1 mm).
Volumetric MRI scans were first bias field corrected and
whole-brain parcellated using the geodesic information flow
(GIF) algorithm [22], which is based on atlas propagation
and label fusion. Volumes of the whole amygdala and of 9
AS were subsequently segmented using a customized
version of the module available in FreeSurfer 6.0 [15] to
adapt the output of GIF to the FreeSurfer format. Based on
anatomical subdivision [9], we combined the nine original
subnuclei and focused the analysis on the following five re-
gions: (1) lateral nucleus; (2) basal and paralaminar nucleus;
(3) accessory basal nucleus (AB); (4) corticoamygdaloid
transition area; and (5) the superficial nuclei (central nu-
cleus, cortical nucleus, medial nucleus, anterior amygdaloid
area) (Fig. 1). Based on the volumes of the left and right
hemispheres extracted from the GIF, we defined the most
severely affected cerebral hemisphere in each patient. This
allows avoidance of the difficulties that commonly arise in
imaging analyses of FTD in which accurate outcomes of
volumetric analyses can be obfuscated by combining people
with predominantly right- or left-hemisphere atrophy in thesame analysis. We then compared AS volumes between
groups within the most and least severely affected hemi-
spheres rather than within right and left sides. However,
we also investigated asymmetry by calculating an asymme-
try index (AI), defined as the absolute difference between the
left and right total amygdalar volumes in relation to the total
bilateral volume: j(Left 2 Right)j/(Left 1 Right).
AS volumes were expressed as a percentage of the total
intracranial volume, computed using SPM12 v6470 (Statis-
tical Parametric Mapping; Wellcome Trust Center for Neu-
roimaging, London, UK) running under Matlab R2014b
(Math Works, Natick, MA) [23]. All segmentations were
visually checked for quality.
Statistical analyses were performed on AS volumes and
AI using the SPSS software (SPSS Inc., Chicago, IL)
v22.0, between control and FTD groups, using an analysis
of variance test adjusting for the scanner type, total intracra-
nial volume, gender, and age. Results were corrected
for multiple comparisons (Bonferroni’s correction) at
P , .005 for the genetic and pathological groups.3. Results
Stratifying by genetics, theMAPT group had the smallest
AS in both hemispheres (37%–43%, P , .0005), whereas
C9orf72 and GRN had similar volume differences in the
most affected hemisphere, with the greatest involvement in
the superficial group and AB (24%–29%, P , .0005) and
the lowest in the lateral nucleus (14%–18%, P , .0005)
(Fig. 2A and Supplementary Table 1). All AS were signifi-
cantly smaller in MAPT than in C9orf72 and GRN
(P , .0005; Supplementary Table 2).
Stratifying by pathology, the FTDP-17, TDP-43 type C,
and Pick’s disease groups were the most impaired, especially
for the superficial (39%–47%), AB (38%–50%), and basal/
paralaminar subnuclei (35%–39%, P , .0005) in the most
Fig. 2. The pattern of atrophy in the amygdala subnuclei in the genetic (A) and pathologically confirmed (B) FTD cases. The color bar denotes the percentage
difference in volume from controls. 1 denotes the most affected hemisphere; 2 denotes the least-affected hemisphere. FTD, frontotemporal dementia.
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Similar toMAPT mutations, the FTDP-17 group showed se-
vere volumetric differences compared with controls in the
least-affected hemisphere as well (AB and basal/paralami-
nar subnuclei: 47%–48%, P , .0005). In TDP-43 type A
and type B, the smallest AS when compared with controls
were the superficial and AB in both hemispheres (21%–
24% and 25%–30% for superficial; 20%–23% and 23%–
28% for AB, respectively, P , .003). Fused in sarcoma
showed a homogenous involvement across all AS (28%–
31% for the most affected side and 26%–28% for the least
affected, P , .003). The most affected AS in progressive
supranuclear palsy was of the superficial group (30%–
33%), but without involvement of the corticoamygdaloid
transition area. Corticobasal degeneration appeared to be
the least-affected group (18%–24%, P , .0005) (Fig. 2B
and Supplementary Table 1). Comparisons between the
pathological groups are reported in the Supplementary
Table 2.
For most groups, no differences were seen between the
right and left amygdalae, except for the GRN (0.067
[0.060]), Pick’s disease (0.110 [0.065]), corticobasal degen-
eration (0.075 [0.064]), and TDP-43 type C (0.140 [0.072])
groups, which had an AI significantly greater than that of
controls (0.030 [0.026]) (P , .003).4. Discussion
In a cohort of patients with genetic and pathologically
confirmed FTD, we have shown that AS are the mostaffected in MAPT/FTDP-17, Pick’s disease, and TDP-43
type C groups, with the most affected subnuclei across
most groups being the superficial, AB, and basal/paralami-
nar ones.
Our results showing amygdalar involvement across all
forms of FTD are consistent with and extend the work of
previous imaging and neuropathological studies
[7,8,24,25]. Similarly, our work is consistent with prior
studies showing particular involvement of the amygdala in
patients with MAPT mutations/FTDP-17 pathology [4–6].
However, in this study, we were able to determine
in vivo localization of the volume difference within the
amygdala, where the most affected nuclei were the super-
ficial, AB, and basal/paralaminar nuclei, which form part
of the reward system, and these were also found to be
connected to key limbic brain regions (Fig. 1). Impair-
ment of the reward system is regularly seen in patients
with FTD but is not universal to all people; previous
studies have shown problems with changes in appetite
and sexual behavior in patients with FTD due to MAPT
mutations, Pick’s disease, and TDP-43 type C [26],
which were the most frequently diagnosed condition as
reported in this study. AS are also involved in emotional
processing, which is known to be impaired in both
behavioral variant of frontotemporal dementia and se-
mantic variant of primary progressive aphasia (which
form the majority of the TDP-43 type C cases) [27].
Consistent with our findings, one previous functional
magnetic resonance imaging study [28] has shown that
specific AS associated with difficulty in recognizing
M. Bocchetta et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 11 (2019) 136-141140facial emotional expressions in people with behavioral
variant of frontotemporal dementia are the superficial
and basolateral nuclei.
The reason for differential AS involvement in the
different genetic and pathological forms of FTD and how
this may lead to different symptoms is currently unclear. It
is likely that different neuronal networks have specific
vulnerability to particular pathological proteins, and our
work here suggests that specific AS may be vulnerable in
different proteinopathies [29] rather than the entire amyg-
dala. Future research, brain imaging, both on a macroscopic
level and at the cellular level, is needed to investigate this
further.
Limitations of this study include the use of different scan-
ners (three manufacturers, two different magnetic fields:
1.5T and 3T) with slightly different MRI sequence types.
Even if we correct for the scanner type and gender in the sta-
tistical model, we cannot completely remove some of the
intrinsic heterogeneity due to these variables. We used an
automated method to extract the AS volumes, which is not
as accurate as their manual segmentation on dedicated
MRIs or on brain tissue postmortem, but we combined the
smallest AS into larger groups of nuclei to remove the effect
of their less reliable delineation on T1MRIs andmanual seg-
mentation is extremely time-consuming and labor-intensive
in such a large cohort.
Future studies of functional and diffusion MRI will be
helpful to investigate, in detail, the different connections
of the AS in each form of FTD. Furthermore, longitudinal
studies, potentially including mutation carriers in their pre-
symptomatic stage, will help to understand the differential
involvement of AS over the course of the disease.Acknowledgments
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1. Systematic review: The amygdala is known to be
atrophic in cases of frontotemporal dementia
(FTD), but no prior study has specifically investi-
gated the different amygdalar subnuclei. We re-
viewed the existing literature on PubMed Central
on imaging and pathological studies of the amygdala
in cases with FTD.
2. Interpretation: We showed in vivo differential amyg-
dalar involvement across all forms of FTD. Our find-
ings are consistent with and extend the previous
studies. We showed that the most affected subnuclei
form part of a network of regions that control reward
and emotion regulation, functions known to be
particularly affected in FTD.
3. Future directions: Further studies on connectivity of the
amygdalar subnuclei, together with longitudinal studies,
including presymptomatic mutation carriers, are key to
better understand the differential involvement of the
amygdalar subnuclei over the course of the disease.References
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